Cargando…
Nanoparticles modified by polydopamine: Working as “drug” carriers
Inspired by the mechanism of mussel adhesion, polydopamine (PDA), a versatile polymer for surface modification has been discovered. Owing to its unique properties like extraordinary adhesiveness, excellent biocompatibility, mild synthesis requirements, as well as distinctive drug loading approach, s...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KeAi Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170807/ https://www.ncbi.nlm.nih.gov/pubmed/32322763 http://dx.doi.org/10.1016/j.bioactmat.2020.04.003 |
_version_ | 1783523948923715584 |
---|---|
author | Jin, Anting Wang, Yitong Lin, Kaili Jiang, Lingyong |
author_facet | Jin, Anting Wang, Yitong Lin, Kaili Jiang, Lingyong |
author_sort | Jin, Anting |
collection | PubMed |
description | Inspired by the mechanism of mussel adhesion, polydopamine (PDA), a versatile polymer for surface modification has been discovered. Owing to its unique properties like extraordinary adhesiveness, excellent biocompatibility, mild synthesis requirements, as well as distinctive drug loading approach, strong photothermal conversion capacity and reactive oxygen species (ROS) scavenging facility, various PDA-modified nanoparticles have been desired as drug carriers. These nanoparticles with diverse nanostructures are exploited in multifunctions, consisting of targeting, imaging, chemical treatment (CT), photodynamic therapy (PDT), photothermal therapy (PTT), tissue regeneration ability, therefore have attracted great attentions in plenty biomedical applications. Herein, recent progress of PDA-modified nanoparticle drug carriers in cancer therapy, antibiosis, prevention of inflammation, theranostics, vaccine delivery and adjuvant, tissue repair and implant materials are reviewed, including preparation of PDA-modified nanoparticle drug carriers with various nanostructures and their drug loading strategies, basic roles of PDA surface modification, etc. The advantages of PDA modification in overcoming the existing limitations of cancer therapy, antibiosis, tissue repair and the developing trends in the future of PDA-modified nanoparticle drug carriers are also discussed. |
format | Online Article Text |
id | pubmed-7170807 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | KeAi Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-71708072020-04-22 Nanoparticles modified by polydopamine: Working as “drug” carriers Jin, Anting Wang, Yitong Lin, Kaili Jiang, Lingyong Bioact Mater Article Inspired by the mechanism of mussel adhesion, polydopamine (PDA), a versatile polymer for surface modification has been discovered. Owing to its unique properties like extraordinary adhesiveness, excellent biocompatibility, mild synthesis requirements, as well as distinctive drug loading approach, strong photothermal conversion capacity and reactive oxygen species (ROS) scavenging facility, various PDA-modified nanoparticles have been desired as drug carriers. These nanoparticles with diverse nanostructures are exploited in multifunctions, consisting of targeting, imaging, chemical treatment (CT), photodynamic therapy (PDT), photothermal therapy (PTT), tissue regeneration ability, therefore have attracted great attentions in plenty biomedical applications. Herein, recent progress of PDA-modified nanoparticle drug carriers in cancer therapy, antibiosis, prevention of inflammation, theranostics, vaccine delivery and adjuvant, tissue repair and implant materials are reviewed, including preparation of PDA-modified nanoparticle drug carriers with various nanostructures and their drug loading strategies, basic roles of PDA surface modification, etc. The advantages of PDA modification in overcoming the existing limitations of cancer therapy, antibiosis, tissue repair and the developing trends in the future of PDA-modified nanoparticle drug carriers are also discussed. KeAi Publishing 2020-04-18 /pmc/articles/PMC7170807/ /pubmed/32322763 http://dx.doi.org/10.1016/j.bioactmat.2020.04.003 Text en © 2020 Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Jin, Anting Wang, Yitong Lin, Kaili Jiang, Lingyong Nanoparticles modified by polydopamine: Working as “drug” carriers |
title | Nanoparticles modified by polydopamine: Working as “drug” carriers |
title_full | Nanoparticles modified by polydopamine: Working as “drug” carriers |
title_fullStr | Nanoparticles modified by polydopamine: Working as “drug” carriers |
title_full_unstemmed | Nanoparticles modified by polydopamine: Working as “drug” carriers |
title_short | Nanoparticles modified by polydopamine: Working as “drug” carriers |
title_sort | nanoparticles modified by polydopamine: working as “drug” carriers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170807/ https://www.ncbi.nlm.nih.gov/pubmed/32322763 http://dx.doi.org/10.1016/j.bioactmat.2020.04.003 |
work_keys_str_mv | AT jinanting nanoparticlesmodifiedbypolydopamineworkingasdrugcarriers AT wangyitong nanoparticlesmodifiedbypolydopamineworkingasdrugcarriers AT linkaili nanoparticlesmodifiedbypolydopamineworkingasdrugcarriers AT jianglingyong nanoparticlesmodifiedbypolydopamineworkingasdrugcarriers |